Full-Time

Senior Scientist

Bio AI

Earli, Inc.

Earli, Inc.

11-50 employees

Biotech platform for early cancer detection

Compensation Overview

$205k - $235k/yr

Company Does Not Provide H1B Sponsorship

San Carlos, CA, USA

In Person

Category
Biology & Biotech (3)
, ,
Required Skills
Python
R
Machine Learning
Google Cloud Platform
Requirements
  • Master’s or PhD degree in a relevant field (bioengineering, computer science, data science, etc.) with a minimum of 3 years of hands-on experience using artificial intelligence and machine learning applied to genomic and bioinformatic data using state-of-the-art GenAI models
  • Deep, direct expertise (preferably with high-quality publications) in developing novel GenAI models trained on massive biological data, with hands-on experience in model training, fine-tuning, and in silico evaluation
  • Expert level competence in data analysis on large and complex empirical data such as MPRA data and multi-modal omics data
  • Familiarity with and prior experience collaborating with wet lab scientists to generate and curate high-throughput screening data on large libraries of DNA or RNA sequences
  • Proficiency in routine bioinformatic analyses such as differential gene expression, ATAC-seq and RNA-seq analysis
  • Expert level coding skills in Python and R
  • Basic knowledge of fundamental cancer biology; deep expertise in cancer-omics, biomarkers, targets and pathways is preferred
  • Excellent verbal and written communication as well as interpersonal skills
  • Ability to multi-task, manage multiple projects simultaneously and work effectively within a team
  • Ability to think independently and fully integrate into a high achieving team environment
Responsibilities
  • Leverage cutting-edge machine learning, bioinformatics, and high-throughput assay data to design cancer-specific synthetic promoters and novel genetic medicines that will directly impact Earli’s clinical pipeline
  • Train generative AI models for designing genetic medicines by leveraging Earli’s proprietary Massively Parallel Reporter Assay data as well as external data sets
  • Contribute to wet lab experimental design and data evaluation to benchmark AI model performance against ground truth wet lab data and create a rapid iteration loop
  • Perform routine computational analyses to analyze MPRA and other large experimental datasets using existing packages as well as bespoke analysis where needed, and provide accessible interfaces (e.g. Shiny apps) for routine data analysis (e.g. RNAseq profiling) for team members
  • Perform routine bioinformatic analyses on multi-modal omics data (RNAseq and scRNA-seq, ATAC-seq, proteomics, phospho-proteomics etc.) using individual as well as coherent multi-omic ML-based pipelines
  • Routinely deploy code and execute on Earli’s infrastructure hosted by Cloud Service Providers (e.g. Google Cloud Platform) with appropriate engineering adaptations as needed, and help develop and work within budgets for GPU usage/compute
Desired Qualifications
  • Deep expertise in cancer-omics, biomarkers, targets and pathways is preferred

Earli is developing an early cancer-detection platform that uses programmable genetic constructs, called Synthetic Bioclassifiers, which enter cells and activate only in cancer cells. When activated, these constructs make cancer cells produce a specific protein that is released into the bloodstream, serving as a detectable biomarker for early cancer detection. The approach aims to distinguish cancerous from healthy cells by programming the system to reveal cancer signals, addressing limitations of traditional liquid biopsies. Earli plans to commercialize the diagnostic platform through partnerships with healthcare providers and pharmaceutical companies, with Accenture having invested in the company as part of its growth strategy.

Company Size

11-50

Company Stage

Series A

Total Funding

$59.5M

Headquarters

San Francisco, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Advanced from stealth to human lung cancer clinical trials in 2.5 years, ahead of liquid biopsy competitors.
  • $104M total funding including Accenture Ventures and Alderline Group validates technology and enterprise partnership potential.
  • Addressable market exceeds one million annual lives if platform achieves clinical efficacy and regulatory approval.

What critics are saying

  • LNP delivery platform dependency creates supply chain vulnerability threatening clinical trial timelines and commercialization.
  • Platform explicitly limited to single-cancer indications, restricting total addressable market versus pan-cancer competitors.
  • Lung cancer clinical trial failure would invalidate core technology thesis and eliminate near-term revenue pathways.

What makes Earli, Inc. unique

  • Synthetic biomarkers force cancer cells to autonomously produce detectable signals, overcoming early-stage tumor invisibility.
  • AI-designed genetic switches enable dual-application revenue: diagnostics and therapeutic immune-oncology drug production.
  • Platform technology detects cancer at Stages 1-2 via non-invasive blood samples and PET scans.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Earli, Inc. who can refer or advise you

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
Entrepreneur Media
Dec 19th, 2024
Earli Raises $60M for Cancer Innovation

Earli, a startup founded by Cyriac Roeding, Dr. David Suhy, and the late Dr. Sanjiv Sam Gambhir, has raised $60 million to advance its cutting-edge cancer detection and treatment technology. The company engineers synthetic biomarkers within cancer cells, enabling earlier and more accurate detection and treatment. Following six years of research, Earli is preparing for human clinical trials, starting with lung cancer, and aims to expand its platform to other cancer types.

PR Times
Nov 3rd, 2024
GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資

GLIN Impact Capital 有限責任事業組合のプレスリリース(2024年10月31日 12時10分)GLIN Impact Capital、がんの早期検出と即時治療につながる技術を開発する米Earliに出資

Business Wire
Aug 20th, 2024
Accenture Invests in Earli Inc. to Advance Technologies for Early Cancer Detection

Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company.

Westwood & Wilshire
Oct 6th, 2021
Earli hired Maggie Louie as Vice President of Biology on Oct 6th 21'.

Earli, the company pioneering a new approach to cancer diagnostics by forcing cancer cells to produce synthetic biomarkers, announced today that Maggie Louie accepted the roll of Vice President of Biology.

Earli Inc.
Jun 30th, 2021
Earli hired Shereen Asad on Jan 1st 19'.

When Shereen Asad joined Earli as its sixth employee in 2019, her job description didn’t exactly say anything about selling human blood samples.